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Immunotherapy is considered to be the only curative treatment for allergic diseases such as pollinosis, perennial rhinitis, asthma,
and food allergy. The sublingual route is widely applied for immunotherapy for allergy, instead of the conventional administration
by subcutaneous route. A recent meta-analysis of sublingual immunotherapy (SLIT) has shown that this approach is safe, has
positive clinical eﬀects, and provides prolonged therapeutic eﬀects after discontinuation of treatment. However, the mechanism
of SLIT and associated biomarkers are not fully understood. Biomarkers that change after or during SLIT have been reported
and may be useful for response monitoring or as prognostic indicators for SLIT. In this review, we focus on the safety, therapeutic
eﬀects,includingprolongedeﬀectsaftertreatment,andnewmethodsofSLIT.Wealsodiscussresponsemonitoringandprognostic
biomarkers for SLIT. Finally, we discuss immunological mechanisms of SLIT with a focus on oral dendritic cells and facilitated
antigen presentation.
1.Introduction
Allergic rhinitis is the most prevalent type I allergy, and
pollen grains, mite, and mold are common causative aller-
gens for seasonal or perennial rhinitis. Antihistamines, leu-
kotriene inhibitors, and nasal steroids are commonly used to
treat respiratory allergy, but these drugs sometimes have side
eﬀects that induce impaired performance [1, 2]. Almost 100
yearshavepassedsincetheﬁrstreportofimmunotherapy for
pollinosis in 1911 [3]. Subsequently, the protocol for aller-
gen-speciﬁcimmunotherapyhasimprovedtoincreaseefﬁca-
cy and safety through coinjection or conjugation of allergens
with an immunomodulatory adjuvant, premedication with
an antihistamine or anti-human IgE antibody, or use of a
rush protocol to shorten the duration of the updosing phase
[4–8]. The injection route for allergens has also been exam-
ined in trials of modiﬁed allergens to shorten the schedule
and to increase the safety for immunotherapy [9, 10]. In
the last few decades, sublingual administration has been
recognized as a route of administration of allergens that is
safer than subcutaneous injection, and there is increasing
evidence that the therapeutic eﬀects of sublingual immun-
otherapy (SLIT) are comparable with those of traditional
subcutaneous immunotherapy (SCIT) [11].
In this review, we focus on the therapeutic eﬀects of SLIT
and the problems to be solved in future clinical studies. We
also discuss recent ﬁndings for prospective and response-
monitoringbiomarkersforSLIT,andweexaminethecellular
mechanisms of SLIT.
2. Safety andTherapeutic Effects of SLIT
Increasing numbers of clinical trials and meta-analyses have
shown positive clinical eﬀects and safety of SLIT. However,
severalcasereportshavealsodescribedanaphylacticshockor
severe fatal reactions induced by sublingual administration
ofallergens[12–17].Inthereports,fourpatientsexperienced
severe side eﬀects with SCIT and discontinued the treatment2 Journal of Allergy
prior to SLIT [15, 16]. Patients who have experienced severe
sideeﬀectsinSCITmaybeatriskforaseverefatalreactionin
SLIT. To prevent an allergen overdose, a tablet or solid form
for sublingual administration may be better than the use of
an atomizer or dispenser for administration of liquid aller-
gens, especially for young children. Despite the few case re-
ports of severe fatal events, life-threatening severe fatal reac-
tions have not been found in clinical trials [18]. Therefore,
SLIT is considered to be a safe treatment in which reactions
such as anaphylaxis can be avoided by using correct clinical
protocols.
It takes a few weeks to six months to reach a maintenance
dose using SCIT with a previous updosing phase to reduce
the risk of side eﬀects [19]. In some studies, a build-up phase
is used for SLIT before administering the maintenance dose
of allergens. A comparison of the clinical eﬀects and safety
among four diﬀerent SLIT regimes for grass pollen allergy
using a mixture of extracts of ﬁve grass pollens (Anthoxan-
thum odoratum, Dactylis glomerata, Lolium parenne, Phleum
pratense,a n dPoa pratensis) concluded that a short build-
up phase reduces the incidence of adverse events in admin-
istration of high-dose SLIT [20]. In this phase I study, the
numbers of adverse events were compared among four active
groups with a build-up phase repeating each concentration
from 100 to 500IR for 2 days (N = 6), a single daily
build-up phase of 100 to 500IR (N = 6), and no build-
up phase for doses of 300IR (N = 6) or 500IR (N = 5).
All groups showed mild and moderate adverse events, but
onlythegroupadministered500IRwithoutabuild-upphase
showed severe local adverse events (swelling of throat). A
placebo group (N = 7) showed only mild adverse events.
Another study compared the safety and eﬃcacy among 3
SLIT groups with a build-up phase of 500 to 1,000AU
for 4 days, 300 to 1,200AU for 4 days, and no build-up
phase for a dose of 1,000AU, using orosoluble tablets of a
monomeric carbamylated allergoid [21]. Safety and eﬃcacy
were comparable among these groups, based on evaluation
using a Visual Analog Scale (VAS), the Symptom Medication
Score (SMS), and a nasal provocation test. An ultrarush
sched-ule for SLIT has also been shown to be safe during the
updosing phase, but severe systemic and local adverse events
may occur in the maintenance phase [22, 23]. In contrast,
urticaria has been reported to occur in an ultrarush protocol
[24]. The safety of this protocol may depend on the type and
biological function of the causal allergens. It has also been
suggested that the build-up phase for SLIT can be omitted or
shortened compared to that for SCIT [25].
A recent meta-analysis found positive clinical eﬀects of
SLITbasedontheresultsfrom49papersdescribingrandom-
ized, double-blind, and placebo-controlled (DBPC) trials
[18]. The standardized mean diﬀerences (SMDs) for the
symptom and medication scores were −0.49 (P<0.00001)
and −0.32 (P<0.00001), respectively, in favor of active
treatment (active; N = 2,333, placebo; N = 2,256). A
meta-analysis of SLIT for grass pollinosis gave SMDs for the
symptom (active; N = 1,518, placebo; N = 1,453) and
medication (active; N = 1,428, placebo; N = 1,358) scores
of −0.32 (P<0.0001) and −0.33 (P<0.0002), respectively,
in favor of active treatment compared with placebo [26].
Both meta-analyses showed positive therapeutic eﬀects of
SLIT, especially for seasonal rhinitis, and these eﬀects are
comparable with those of SCIT [18, 27–29]. It has also
been suggested that immunotherapy with SLIT and SCIT
in combination may be beneﬁcial [30]. In this study, 60
children with mild or moderate asthma or rhinitis who were
monosensitized to house dust mite received injection of a
mixture of Dermatophagoides allergens in a glycerinated so-
lution. SCIT was used in a build-up phase for 16 weeks and
was followed by SLIT three times a week as the maintenance
phase. The clinical eﬀects of SLIT were less than those of
SCIT after 4 and 18 months and comparable after 12 months
of treatment, based on the required dose of inhaled corti-
costeroids and the number of asthma attacks per year. SCIT
and combination therapy of SLIT and SCIT signiﬁcantly
decreasedthedoseofinhaledcorticosteroidsandthenumber
of asthma attacks at 4, 12, and 18 months and signiﬁcantly
improved the VAS for rhinitis. An advantage of SLIT is that
sublingual self-administration can be performed at home
duringthemaintenancephase,avoidingtheneedforpatients
to go to clinic for subcutaneous injection of allergens.
There is also increasing evidence for clinical eﬀects after
an extended period of SLIT and for prolonged clinical
effects after treatment [31]. SLIT in 24 children with respira-
tory symptoms due to monosensitization to house dust mite
showed a lack of positive clinical eﬀects in the ﬁrst year, but
signiﬁcant amelioration of rhinitis and asthma in the second
andthirdyearscomparedtotheﬁrstyearoftreatment[32].A
study of 137 patients allergic to house dust mite also showed
clinical eﬀects in 2-year and 3-year SLIT and prolonged
therapeutic eﬀects at 4 and 3 years, respectively, after these
treatments [33]. Scores for nasal airway resistance, secretion,
symptoms, and skin prick test were signiﬁcantly reduced at
the end of the ﬁrst year, and the nasal secretion score was
signiﬁcantly reduced at the end of the second year of treat-
ment. Two-year SLIT signiﬁcantly attenuated nasal airway
resistance, secretion, sneezing, symptoms, and skin prick
scores at 1 and 4 years after treatment compared with the
respective scores at the start of treatment although all scores
except for nasal airway resistance at 4 years after treatment
were slightly, but signiﬁcantly, higher than those at the end
of treatment. Three-year SLIT signiﬁcantly attenuated these
scores at the end of treatment, and total score of nasal airway
resistance, secretion, and sneezing, score for the nasal airway
resistance,andsymptom scoreat3yearsaftertreatmentwere
similar to or lower than those at the end of treatment.
Carry-overeﬀectsofSLITaresupportedbyotherstudies.
DBPC trials of 3-year SLIT for grass pollen allergy showed
significantly decreased scores for symptom and the rhino-
conjunctivitis quality-of-life questionnaire (RQLQ), and
SMS and the medication score tended to decrease with active
treatment compared with those for placebo at 1 year after
SLIT[34,35].Ourrecentresultsalsosuggesta1-yearprolon-
gation of clinical eﬀects after 2-year SLIT for Japanese cedar
pollinosis [36]. Analysis of 88 participants (SLIT; N = 51,
placebo; N = 37) showed positive therapeutic eﬀects in the
second year of SLIT compared with placebo (reduction of
SMS by 21%, P = 0.02) and at 1 year after treatment (23%,
P = 0.03) (Figure 1) .Ar e c e n tp h a s eI I It r i a lp e r f o r m e da sJournal of Allergy 3
a large-scale randomized, DBPC study using a 75,000 SQ-
T/2,800 BAU tablet in 257 subjects allergic to grass pollen
also has shown that 3-year SLIT signiﬁcantly decreased the
meanrhinoconjunctivitissymptomandmedicationscoresat
1 year after treatment compared with placebo. The results
showed reductions of symptom scores of 31%, 36%, 29%,
and 26% and reductions of medication scores of 38%, 45%,
40%, and 29% after 1, 2, and 3 years of treatment and after a
follow-upyear,respectively[37].Long-lastingeﬀectsafter3-,
4-, and 5-year SLIT were evaluated in a 15-year prospective
open controlled study in 59 patients with respiratory allergy
for mite [38]. A decreased SMS of <50% of the baseline score
(at the start of treatment) was found over the following 6
years after 3-year SLIT, and over 8 years after 4- and 5-year
SLIT. The SMS after loss of the prolonged therapeutic eﬀects
increased to levels comparable with those in the control
group. Signiﬁcant clinical eﬀects were obtained in a second
course of SLIT given after the initial eﬀects had vanished.
3. Unmet Problems in SLIT
Compliance with self-administration at home may be an
important factor in the therapeutic eﬀect of SLIT. Compli-
ance with SLIT is likely to be similar to that for other self-
administered drug treatments for allergy [11], and education
on the SLIT protocol is needed for good compliance [39,
40]. Checking the compliance of each patient based on the
amount of remaining vials or tablets may also be important
for evaluating the eﬃcacy of SLIT in clinical trials [34]. A
device that reminds patients about intake of allergens may be
useful to achieve good compliance in long term administra-
tion and to improve the eﬃcacy of SLIT [41]. Delivery as a
tablet or solid form may be better than an aqueous solution
using an atomizer or dispenser to achieve good compliance
andtoholdallergensstablyunderthetonguebecausehuman
error or bad conditions of a nozzle may lead to administra-
tion of an inaccurate amount of liquid drops. Such mistakes
may also increase the risk of adverse reactions [17].
Bystander therapeutic eﬀects of SLIT using allergens
from a single source with polysensitized patients are uncer-
tain. Inferior therapeutic eﬀects for a polysensitized popu-
lation have been reported compared with a monosensitized
population [42]. Recent ﬁndings have shown that the use of
bothsingleandmixedallergenextractsimprovedmeanQOL
scores, increased threshold of a titrated nasal challenge, and
decreased skin prick tests reactivity in polysensitized patients
[43–45]. The eﬃcacy of SLIT for polysensitized patients has
also been found to be comparable with that for monosen-
sitized patients [28]. Furthermore, SLIT for monosensitized
(rhinitis only) and polysensitized (rhinitis and asthma) pa-
tients prevented or reduced additional sensitization com-
pared with drug treatment [46, 47]. These preventive eﬀects
of SLIT were clearer for monosensitized patients. In con-
trast, SLIT for birch pollinosis was not eﬀective against an al-
ready established apple allergy [48]. Mal d 1, a major aller-
gen in apple, has 64% identity in amino acid sequence with
Bet v 1, a major allergen in birch, and these allergens are
cross-reactiveinIgE-bindingandT-cellactivation.Bystander
eﬀects of SLIT using allergens from a single source for pa-
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Figure 1:Clinicalscoresin2-yearSLITandat1yearaftertreatment
[36]. (a) Average daily SMSs during a 2-year course of SLIT and at
1 year after treatment are plotted for the SLIT and placebo (Plc)
groups. ∗P<0.05 (unpaired Student t-test). (b) Percentage average
SMSs for the SLIT group based on a value of 100% for the placebo
group.
tients with other established allergies may depend on the
allergens used for immunotherapy and the degree of sensiti-
zation to the allergy. Further clinical trials and meta-analyses
are needed to evaluate the bystander and prophylactic eﬀects
of SLIT.
In 2010, the World Allergy Organization deﬁned a sys-
temic reaction grading system for scoring of adverse reac-
tions by SCIT to enable comparison of the severity of adverse
events among clinical trials [49]. A similar approach to eval-
uation of clinical eﬀects and adverse events in SLIT is need-
ed to compare the clinical eﬀects and therapeutic efﬁcacy
among studies that diﬀer in allergen, dose, and method
and protocol of administration. This will permit improved
meta-analyses. Currently, it is diﬃcult to optimize the SLIT
protocol using results from multiple clinical trials that
used diﬀerent methods for evaluation of therapeutic eﬀects,
such as cumulative or average scores for symptoms and4 Journal of Allergy
medication, QOL, VAS, local symptoms, and days with mild
or severe symptoms over periods of days, months, seasons,
and years [18, 50, 51]. It will be diﬃcult to score the severity
of allergic symptoms using the same grading system because
both the pattern and main organ in which symptoms appear
may diﬀer among seasonal or perennial allergies in various
areas. However, a scoring or grading system for use in sci-
entific reports is needed as a minimum requirement to per-
mit improved understanding by readers.
4. Trials of Adjuvant Therapy with SLIT
Coadministration of an adjuvant with allergens may achieve
more eﬃcient and eﬀective SLIT. Many studies in mouse
models of asthma or rhinitis have shown increased eﬀects
of SLIT with adjuvant therapy. In most cases, the adjuvant
is used to enhance development or activation of regulatory
T cells (Treg) or increase adherence or permeability of al-
lergens in sublingual mucosa to enhance uptake by antigen-
presenting cells(APCs)suchasmucosaldendritic cells(DC).
Sublingual administration of an antigen conjugated with the
nontoxic B subunit of cholera toxin to mice signiﬁcantly
induced antigen-speciﬁc Foxp3+CD4+ T cells in cervical
lymph nodes and spleen and suppressed proliferation of cells
fromcervicallymphnodesafterstimulationwithantigentoa
greater extent than that after treatment with the unmodiﬁed
antigen. The serum TGF-β level was also higher after admin-
istration of the modiﬁed antigen compared to the unmodi-
ﬁed antigen [52]. Sublingual coadministration of an antigen
with either 1,25-dihydroxyvitamin D3 plus dexamethasone
(VitD3/DEX) or Lactobacillus plantarum suppressed airway
hyperresponsiveness (measured as PenH) compared with
antigen alone, and coadministration with VitD3/DEX signif-
icantly induced Foxp3+ cells in mice [53]. Another mouse
study supported the adjuvant activity of lactic acid bacteria
in enhancing the therapeutic eﬀects of SLIT [54]. A study
using polymerized carbohydrate as a mucoadhesive adjuvant
showed superior reduction of established airway hyperre-
sponsiveness (PenH) and lung inﬂammation compared to
administrationofantigenaloneorphosphate-buﬀeredsaline
[55]. In this study, IL5 and IL10 production from spleno-
cytes was reduced after stimulation with antigen in mice-
administered antigen with adjuvant compared with mice-
administered PBS or antigen alone. The therapeutic eﬀects
of adjuvant SLIT are also under evaluation in humans. In a
Phase I/IIa study, coadministration of grass allergens with a
high dose of monophosphoryl lipid A, an agonist for toll-
like receptor 4, signiﬁcantly increased the rate of negative
ﬁndings in a nasal challenge test at two weeks after comple-
tion of 8-week treatment [56]. Further large scale studies are
needed to evaluate the eﬃcacy of adjuvant SLIT in humans.
5. Recent Findings on Biomarkers for SLIT
Candidate biomarkers for response-monitoring or prognosis
have been proposed and evaluated in many studies [4,
57, 58]. IL10 and Treg cells appear to be involved in the
therapeutic mechanism of SLIT [59–61]. We reported up-
regulation of antigen-speciﬁc Treg cells (IL10+Foxp3+ cells)
in CD25+CD4+ leukocytes from pre- to postpollen season as
a response-monitoring biomarker for SLIT [36, 62]. Among
patients treated with SLIT, total QOL and QOL-symptom
scores after 2 years of treatment signiﬁcantly improved in
a subgroup with increased Treg cells compared with the
placebo group, whereas the scores in a subgroup with de-
creased Treg cells were similar to those in the placebo group
(Figure 2(a)). We also proposed that the ratio of antigen-
specific IgE to total IgE (sIgE/tIgE) was a candidate as a
prognostic biomarker for SLIT in a DBPC trial [36]. SMS in
the SLIT group was correlated with the sIgE/tIgE ratio before
treatment and was signiﬁcantly improved in patients with a
low sIgE/tIgE ratio compared to that in patients with a high
sIgE/tIgE ratio (Figures 2(b) and 2(c))[ 36]. The sIgE/tIgE
ratio has been found to be signiﬁcantly higher in responders
than in nonresponders following 4-year im-munotherapy
[63]. In this study, responders to the immunotherapy (42
patients for SCIT and 103 patients for SLIT) showed higher
grass-ormite-speciﬁcIgE/tIgEratio thannonresponders (34
patients for SCIT and 100 patients for SLIT) evaluated with
VAS score. In our trial, this ratio did not diﬀer significantly
between responders and nonresponders [36]. Further vali-
dation studies with a large sample size are needed before
these biomarkers can be applied in the clinical management
of SLIT.
Upregulation of regulatory molecules after SLIT has
been reported [57, 64] and programmed cell death ligand 1
(PDL1), IL10, and IgG4 may serve as response-monitoring
biomarkers for SLIT [65]. In this report, all patients who
received preseasonal, seasonal, and prolonged SLIT had in-
creased percentages of PDL1+ and IL10+PDL1+ cells among
CD14+ and CD19+ cells after stimulation with antigen in
pollen season, compared to a placebo group. PDL1 is in-
volved in induction and maintenance of Foxp3+CD4+ Treg
cells in the presence of TGFβ in mouse [66, 67], and induc-
tionofPDL1mayplayanimportantroleininductionofTreg
cells by SLIT.
Apolipoprotein is involved in lipid metabolism and lipid
transport, and apolipoprotein E has roles in lipid antigen
presentation and inhibition of T-cell activation [68, 69].
Upregulation of apolipoprotein A-IV (ApoA-IV) in serum
in pollinosis patients from pre- to postpollen season was
found to be signiﬁcantly greater with SLIT than with placebo
and was inversely correlated with SMS and QOL scores in
the SLIT group [70]. ApoA-IV also signiﬁcantly reduces
histamine release in vitro from basophils taken from patients
[70], and ApoA-IV induced by SLIT may be involved in
downregulation of local or peripheral inﬂammation during
the pollen season.
6. Mechanisms of SLIT
Treg cells play an important role in suppression of Th2
responses and inﬂammatory cells [4, 71]. However, the cells
that induce Treg cells after sublingual administration of
allergens and the mechanism of induction remain unclear.
DCs that preferentially induce Treg cells are thought to be
located in the sublingual mucosa. In a mouse study, three
types of DCs with diﬀerent surface markers were identiﬁedJournal of Allergy 5
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Figure 2: Response-monitoring and prognostic biomarkers for SLIT [36]. (a) Total scores from a QOL questionnaire are plotted for the
SLIT group (All), a subgroup with increased antigen-speciﬁc Treg in the SLIT group (Inc), a subgroup with decreased antigen-speciﬁc Treg
in the SLIT group (Dec), and the placebo (Plc) group after 2 years of treatment. ∗∗P<0.01 (Mann-Whitney U-test). (b) SMSs in the peak
pollen season for patients with low and high sIgE/tIgE ratios in the SLIT group (Act.). ∗P<0.05. (c) Correlation between SMSs after 2
years of SLIT treatment and sIgE/tIgE ratios before treatment in the SLIT (Act, closed diamonds) and placebo (Plc, open diamonds) groups.
Statistical data were obtained with Spearman correlation analysis. N.S.: not signiﬁcant.
within lingual and buccal tissue: CD207+ Langerhans cells in
the mucosa, CD11b+CD11c− and CD11b+CD11c+ myeloid
DCsatthemucosal/submucosalinterface,andB220+120G8+
plasmacytoid DCs [72]. Oral CD11b+CD11c− DCs induced
IFN-γ production by T cells, and oral CD11b+CD11c+ DCs
and B220+120G8+ DCs induced IFN-γ and IL10 production
by T cells in an antigen-speciﬁc manner. These oral DCs may
preferentially skew development to antigen speciﬁc Th1 or
Treg. The function of CD207+ Langerhans cells could not
b ed e t e r m i n e db e c a u s eo fl i m i t e dc e l ln u m b e r s .I nh u m a n s ,
oral mucosal Langerhans cells (oLCs) that constitutively
express FcεRI on the surface have been found in atopic
and nonatopic subjects [73]. Expression levels of FcεRI were
found to be signiﬁcantly correlated with serum IgE levels
in atopic subjects. oLCs also expressed signiﬁcantly higher
amounts of major histocompatibility complex (MHC) I and
II, CD40, CD80, and CD86 compared to skin Langerhans
cells [73]. Toll-like receptor 4-ligation of oLCs has also
been shown to induce production of IL10, TGF-β,I L 2 ,
IFN-γ,a n dF o x p 3[ 74], and oLCs might capture allergens
within sublingual mucosa and present them to T cells to
develop antigen-speciﬁc Treg cells [75, 76]. Further studies
are needed to determine the importance of oral DCs and
oLCs in the therapeutic mechanisms of SLIT.6 Journal of Allergy
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Figure 3:ProposedeﬀectsofSLITonTcells,Bcells,APC,andinﬂammatorycells[57].OralDCsoroLCsmaytakeupallergensadministered
sublingually, followed by induction of Th1 or Treg cells to downregulate Th2 cells and inﬂammatory cells. The Treg cells also activate B cells
to produce blocking antibody, which may inhibit binding between allergens and surface IgE on inﬂammatory cells to prevent secretion of
inﬂammatory mediators and inhibit FAP by APCs or B cells to Th2 cells.
Induction of IgG and IgG4 as blocking antibodies in
SLIT is still under debate [77, 78]. IgE enhances uptake
and presentation of invading antigens by APCs via CD23, a
process known as facilitated antigen presentation (FAP), and
transcytosis by human airway epithelial cells in a CD23-de-
pendent manner [79, 80]. The immune complex of IgE with
antigen binds to CD23, and this binding leads to enhance
antigenpresentationbyAPCstoTcells[79].Thereisincreas-
ing evidence to show that SLIT inhibits FAP by preventing
binding of IgE with antigen or CD23 [81]. Decreased FAP
after immunotherapy is correlated with T-cell activation in
vitro and antigen-speciﬁc IgG titer, and FAP activity tends
to correlate with IgE/IgG4 ratio and symptom score [82–
84]. This inhibition of FAP leads to decrease antigen-speciﬁc
proliferation and IL4, IL5, IL10, and IFN-γ production
from T cells [85]. The inhibition persists over 2 years after
discontinuation of 2-year immunotherapy although speciﬁc
IgG and IgG4 levels decreased to preimmunotherapy levels
[86]. Other factors may also be involved in the mechanism of
FAP by inhibiting CD23 and IgE binding.
7. Conclusions
One of the aims of immunotherapy is to induce tolerance
against invading allergens. The therapeutic eﬀects and efﬁca-
cy of SLIT vary among allergies with diﬀerent causal allergen
sources. Achievement of a level of tolerance at which drugs
are not required and symptoms are absent in the greatest
numbers of patients requires further optimization of proto-
cols and modiﬁcation of SLIT or standardization of allergens
as a SLIT vaccine. Adjuvant SLIT and combination with
other methods may help to achieve more eﬀective SLIT.
The involvement of oral DC, oLCs, Treg, and FAP in the
therapeutic mechanisms of SLIT has been proposed in many
studies in humans and in mice (Figure 3). To determine
the chain of mechanisms of SLIT, more studies are needed
using human materials from clinical trials with large sample
numbers. Understanding the precise mechanisms of SLIT
should facilitate more eﬀective immunotherapy for more
patients with allergies.
Abbreviations
APC: antigen-presenting cells
DBPC: double-blind, placebo-controlled
DC: dendritic cells
SCIT: subcutaneous immunotherapy
SLIT: sublingual immunotherapy
SMD: standardized mean diﬀerence
SMS: symptom-medication score
Treg: regulatory T cells
QOL: quality-of-life
VAS: Visual Analog Scale.
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